Fosmanogepix
 | |
| Clinical data | |
|---|---|
| Other names | APX001, APX-001 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
Fosmanogepix is an experimental
candidaemia, and coccidioidomycosis.[3]
Fosmanogepix is a prodrug and is converted into the active drug form, manogepix in vivo.[4] Manogepix targets the enzyme GWT1 (Glycosylphosphatidylinositol-anchored Wall protein Transfer 1[5]), an enzyme in the glycosylphosphatidylinositol biosynthesis pathway.[6] Inhibiting this enzyme prevents the fungi from properly modifying certain (so called GPI-anchored) proteins essential to the fungal life cycle. This mechanism of action is totally novel; therefore, if approved, fosmanogepix would become a first-in-class medication.[6][7]
In 2023, the drug was given a compassionate use authorization for four patients with Fusarium solani meningitis.[8]
References
- ^ "What we do : Basilea".
- PMID 34626339.
- ^ "Fosmanogepix - Amplyx Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. Retrieved June 27, 2022.
- PMID 33722886.
- ^ "GWT1". Saccharomyces Genome Database. Stanford University. Retrieved 2022-06-28.
- ^ PMID 33105672.
- PMID 34051400.
- S2CID 267547035.